Esonadogene imvoparvovec is under clinical development by Wuhan Neurophth Biological Technology and currently in Phase II for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy). According to GlobalData, Phase II drugs for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Esonadogene imvoparvovec LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Esonadogene imvoparvovec overview

Esonadogene imvoparvovec is under development for the treatment of Leber hereditary optic neuropathy due to mutation of G11778A (ND4) gene. It is administered through intravitreal route. The drug candidate comprises of a recombinant adeno-associated virus vector serotype 2 (AAV2) delivering the human wild-type mitochondrial ND4 gene (rAAV2-ND4 vector). It acts by targeting NADH ubiquinone oxidoreductase chain 4 (ND4).

Wuhan Neurophth Biological Technology overview

Wuhan Neurophth Biological Technology is a clinical-stage in-vivo gene therapy company that discovers and develops gene therapies for people suffering from blindness and other eye diseases. The company is headquartered in Wuhan, Hubei, China.

For a complete picture of Esonadogene imvoparvovec’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.